Incyte stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 67 to 71.
This unique rating measures technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners often have an RS Rating of over 80 in the early stages of their moves. See if Incyte stock can continue to rebound and hit that benchmark.
Can You Really Time The Stock Market?
Is Incyte Stock A Buy?
Incyte stock trading at its 50-day moving average and is building a consolidation with an 83.95 entry. See if the biotech stock can break out in heavy trade.
Earnings growth moved up in the company's most recent report from -3% to 35%, but sales fell from 24% to 16%.
Incyte stock holds the No. 36 rank among its peers in the Medical-Biomed/Biotech industry group. Halozyme Therapeutics, Catalyst Pharmaceuticals and Corcept Therapeutics are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
